Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmory Embolism - Overview
Pulmory Embolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pulmory Embolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pulmory Embolism - Companies Involved in Therapeutics Development
Acticor Biotech SAS
Bio-Synectics Inc
Chi Resources Emde Biological Pharmaceutical Co Ltd
India Lysis Technologies LLC
Kolmar Korea Co Ltd
Les Laboratoires Servier SAS
Supergene LLC
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Verseon Corp
Pulmory Embolism - Drug Profiles
BS-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Pulmory Embolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glenzocimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KKM-183A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reteplase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-62798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Staphylokise - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
urokise - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zifa-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmory Embolism - Dormant Projects
Pulmory Embolism - Discontinued Products
Pulmory Embolism - Product Development Milestones
Featured News & Press Releases
Oct 25, 2017: IU-based drug-discovery startup aims to use notechnology to digest blood clots in lungs
Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Pulmonary Embolism, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Pulmonary Embolism, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pulmonary Embolism - Pipeline by Acticor Biotech SAS, 2021
Pulmonary Embolism - Pipeline by Bio-Synectics Inc, 2021
Pulmonary Embolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2021
Pulmonary Embolism - Pipeline by Indiana Lysis Technologies LLC, 2021
Pulmonary Embolism - Pipeline by Kolmar Korea Co Ltd, 2021
Pulmonary Embolism - Pipeline by Les Laboratoires Servier SAS, 2021
Pulmonary Embolism - Pipeline by Supergene LLC, 2021
Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021
Pulmonary Embolism - Pipeline by Techfields Pharma Co Ltd, 2021
Pulmonary Embolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2021
Pulmonary Embolism - Pipeline by Verseon Corp, 2021
Pulmonary Embolism - Dormant Projects, 2021
Pulmonary Embolism - Discontinued Products, 2021